USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION
The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.
1 . A method for inhibiting platelet aggregation comprising administering a therapeutically effective amount of the metabolite valery 4-hydroxy valsartan or a pharmaceutically acceptable salt thereof, optionally in the presence of a pharmaceutically acceptable carrier, to a patient in need thereof.
2 . A method of for the prevention, delay of progression or treatment of conditions mediated by platelet aggregation comprising administering a therapeutically effective amount of the metabolite valeryl 4-hydroxy valsartan or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
3 . The method of claim 2 wherein the condition mediated by platelet aggregation is acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.
4 . A pharmaceutical composition comprising a therapeutically effective amount of the metabolite valery 4-hydroxy valsartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
5 . Use of the metabolite valeryl 4-hydroxy valsartan or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention, delay of progression or treatment of a disease and disorder mediated by platelet aggregation, in particular, acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.